Donepezil

Introduction Overview

Generic Name

donepezil

Brand Name

Aricept, Aricept ODT

Dosage Form

Tablets (5 mg, 10 mg, 23 mg), Orally disintegrating tablets (ODT) (5 mg, 10 mg)

Drug Class

Cholinesterase inhibitors

Pharmacokinetics

Absorption:
Donepezil exhibits good oral bioavailability with peak plasma concentrations typically reached within 3 to 4 hours after administration. It is well absorbed from the gastrointestinal tract, and the presence of food does not significantly affect the rate or extent of absorption, allowing it to be taken with or without meals. The drug undergoes minimal first-pass metabolism, enhancing its systemic availability. Clinical studies indicate steady-state plasma levels are generally achieved within 15 to 21 days of daily dosing, which aligns with its chronic dosing regimen in Alzheimer's disease management.

Distribution:
Donepezil is extensively distributed throughout the body, with a volume of distribution averaging approximately 12 L/kg, indicating widespread tissue penetration including the central nervous system (CNS). It readily crosses the blood-brain barrier, a critical factor in its efficacy in treating Alzheimer's disease symptoms. Plasma protein binding is moderate, around 96%, primarily to albumin, which may impact its interaction profile and pharmacodynamics. The drug’s distribution into various tissues underpins its ability to increase acetylcholine levels in the brain effectively.

Metabolism:
Donepezil undergoes extensive hepatic metabolism predominantly through the cytochrome P450 enzyme system, especially CYP3A4 and CYP2D6 isoenzymes. It is metabolized to several inactive metabolites, with donepezil N-oxide being a major metabolite detected in plasma. Genetic polymorphisms affecting CYP2D6 can influence donepezil plasma levels and response variability among patients. Additionally, coadministration with CYP3A4 inhibitors or inducers can significantly alter donepezil metabolism, necessitating careful therapeutic monitoring.

Elimination:
Donepezil has a relatively long elimination half-life, averaging approximately 70 hours, which supports once-daily dosing. Its elimination is primarily via hepatic metabolism with subsequent renal excretion of metabolites; less than 7% of the unchanged drug is excreted in the urine. The prolonged half-life permits steady-state concentrations to be reached within one to two weeks. Hepatic or renal impairment can alter pharmacokinetics, potentially necessitating dosage adjustments. Clinical pharmacokinetic studies highlight the need for cautious use in patients with compromised liver or kidney function to avoid accumulation and toxicity.

Dosage Forms

Available Dosage Forms:
- Tablets: 5 mg, 10 mg, 23 mg
- Orally Disintegrating Tablets (ODT): 5 mg, 10 mg

Dosages for Adults and Adolescents:
- Mild to Moderate Alzheimer's Disease:
- Initial dose: 5 mg orally once daily, preferably in the evening before bedtime
- Maintenance dose: 10 mg orally once daily after at least 4 to 6 weeks on 5 mg dose
- Moderate to Severe Alzheimer's Disease:
- Initial dose: 5 mg orally once daily
- Maintenance dose: 10 mg once daily after 4 to 6 weeks on 5 mg
- Dose may be increased to a maximum of 23 mg once daily after a minimum of 3 months on 10 mg dose, depending on patient tolerance and clinical judgment

Specific Patient Populations:
- Elderly: Dosing recommendations remain the same due to donepezil primarily being used in older adults with Alzheimer's disease.
- Hepatic and Renal Impairment: Use with caution; dosage adjustments may be required due to altered metabolism and excretion.
- Patients with difficulty swallowing: The ODT formulation provides an alternative that dissolves on the tongue to facilitate easier administration.

Clinical Guidelines:
Dosing should be individualized based on clinical response and tolerability. The titration to higher doses should consider potential side effects and risk-to-benefit ratio. The recommended evening dosing is to minimize adverse effects such as nausea and to optimize tolerability.

Mechanism Of Action

Donepezil functions as a selective, reversible inhibitor of acetylcholinesterase (AChE), the enzyme responsible for hydrolyzing acetylcholine (ACh) in synaptic clefts. By inhibiting AChE, donepezil increases the concentration and duration of action of acetylcholine at cholinergic synapses, particularly within the central nervous system. This elevation in acetylcholine levels enhances cholinergic neurotransmission, which is typically deficient in Alzheimer's disease due to neuronal loss and functional impairment.

On a molecular level, donepezil binds to the active site of acetylcholinesterase, preventing breakdown of acetylcholine and thereby potentiating its effects on muscarinic and nicotinic receptors involved in cognitive processes. This improved cholinergic neurotransmission is believed to ameliorate symptoms related to memory, attention, and other cognitive functions.

Compared to other cholinesterase inhibitors, donepezil exhibits high selectivity for central nervous system AChE over peripheral cholinesterase, which may reduce peripheral cholinergic side effects. Clinical studies have demonstrated that donepezil can produce modest improvements in cognition, behavior, and global function in patients with mild to severe Alzheimer's disease.

Recent research also suggests that donepezil may exert neuroprotective effects by modulating nicotinic acetylcholine receptors and influencing amyloid-beta plaque aggregation, although these mechanisms are not fully elucidated clinically. Overall, donepezil's pharmacological action supports symptomatic treatment rather than modification of the underlying neurodegenerative process in Alzheimer's disease.

Pharmacological Actions

Selective reversible inhibition of acetylcholinesterase enzyme activity
Enhancement of central cholinergic neurotransmission by increasing acetylcholine availability
Improvement of cognitive functions including memory, attention, and learning
Mild neuroprotective effects through modulation of nicotinic receptors
Central nervous system penetration with minimal peripheral cholinergic side effects
Slowing progression of cognitive decline symptoms in Alzheimer's disease
Potential modulation of amyloid-beta plaque formation pathways
Positive effects on behavioral and functional symptoms in dementia patients
Minimal inhibition of butyrylcholinesterase at therapeutic doses
Once-daily dosing enabled by long elimination half-life
Facilitation of cholinergic signaling in both muscarinic and nicotinic receptor subtypes

Therapeutic Or Clinical Uses

Treatment of mild, moderate, and severe Alzheimer's disease dementia
Improvement of cognitive symptoms including memory deficits and attention problems
Enhancement of patients’ ability to perform activities of daily living
Reduction of behavioral disturbances associated with Alzheimer's disease
Symptomatic management of dementia related to neurodegenerative conditions
Supportive therapy to delay progression of Alzheimer's-related cognitive decline
Adjunctive therapy in patients with moderate to severe dementia to stabilize cognitive function
Use in patients unable to tolerate other cholinesterase inhibitors
Treatment of dementia symptoms in elderly patients with safety and tolerability established
Off-label use in other dementias with cholinergic deficit may be considered under specialist supervision
Maintenance of cognitive function during chronic Alzheimer's disease management

Side Or Adverse Effects

Nausea, often transient and more common during dose escalation
Diarrhea and gastrointestinal discomfort
Vomiting, which may be severe in some cases requiring clinical monitoring
Muscle cramps and generalized weakness
Fatigue and somnolence
Insomnia or disturbed sleep patterns
Loss of appetite or anorexia
Bradycardia and heart block, particularly in patients with preexisting cardiac conditions
Syncope or fainting episodes associated with slow heart rate
Increased gastric acid secretion, raising ulcer and gastrointestinal bleeding risk
Exacerbation of asthma or chronic obstructive pulmonary disease
Urinary retention or difficulty in urination especially in patients with prostate enlargement
Risk of seizures or convulsive events, particularly in susceptible individuals
Allergic reactions including rash, pruritus, and rare anaphylaxis
Potential exaggeration of muscle relaxant effects during anesthesia

Precautions

Monitor cardiac function in patients with known conduction abnormalities or sick sinus syndrome
Use caution in patients with a history of gastric ulcers or gastrointestinal bleeding
Evaluate patients for respiratory diseases such as asthma or COPD before initiation
Be vigilant for signs of urinary retention in men with prostatic hypertrophy
Avoid abrupt discontinuation to prevent rapid cognitive decline
Cautious use in patients with seizure disorders or epilepsy
Inform surgical teams about donepezil use prior to anesthesia due to interactions with neuromuscular blockers
Consider dose adjustments or alternative therapies in hepatic or renal impairment
Assess patient for potential drug interactions especially with anticholinergics and NSAIDs
Advise patients regarding potential side effects impacting driving or alertness
Regularly review therapy efficacy and tolerance given progressive nature of Alzheimer's disease
Weight monitoring due to possible anorexia and gastrointestinal side effects
Pregnancy and lactation use only if clearly needed; potential risks not well defined
Monitor for signs of gastrointestinal bleeding such as melena or hematemesis
Ensure patient adherence and educate on correct administration of ODT formulations

Warnings

Risk of severe bradycardia and heart block, especially in patients with cardiac conduction disorders
Increased risk of gastrointestinal ulceration and bleeding due to enhanced gastric acid secretion
Potential to worsen respiratory conditions such as asthma or chronic obstructive pulmonary disease
May exacerbate muscle relaxant effects during surgical procedures
Possibility of generalized convulsive seizures during treatment
Risk of severe vomiting potentially leading to dehydration or electrolyte imbalance
Risk of syncope which can result in injury from falls
May cause difficulty urinating especially in elderly men with prostatic hypertrophy
Potential allergic reactions including anaphylaxis necessitating immediate medical attention
Use with caution in patients with seizure disorders or predisposition to seizures
Not recommended in patients with known hypersensitivity to donepezil or formulation excipients
Risk of increased side effects or toxicity with concomitant use of CYP3A4 or CYP2D6 inhibitors
Should not be used as a cure; only for symptomatic management of Alzheimer's disease
Patients should be observed for worsening cognitive symptoms or psychiatric effects
Patients and caregivers should be informed about the signs of serious adverse reactions

Contraindication

Known hypersensitivity to donepezil hydrochloride or any components of the formulation
History of severe allergic reaction or anaphylaxis to any cholinesterase inhibitor
Patients with sick sinus syndrome or other significant cardiac conduction abnormalities without pacemaker
Concurrent use with succinylcholine due to potential exacerbation of neuromuscular blockade
Severe hepatic impairment where drug metabolism may be significantly impaired
Severe renal impairment may require contraindication depending on clinical judgment
Patients with active peptic ulcer disease due to risk of bleeding
Uncontrolled asthma or severe chronic obstructive pulmonary disease
Use in pediatric populations due to lack of established safety and efficacy
Known drug interactions posing significant risk as assessed by the prescribing physician

Drug Interactions

Nonsteroidal anti-inflammatory drugs (NSAIDs) increasing risk of gastrointestinal bleeding when used concomitantly
Anticholinergic agents such as benztropine or scopolamine antagonize the therapeutic effects of donepezil
Neuromuscular blocking agents like succinylcholine may have potentiated or prolonged effects
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase plasma concentrations of donepezil
CYP2D6 inhibitors (e.g., quinidine, fluoxetine) may raise donepezil levels and risk of toxicity
Cholinergic agonists could enhance cholinergic side effects when combined with donepezil
Drugs affecting heart rate or conduction (e.g., beta-blockers, digoxin) require monitoring due to additive bradycardia risk
Concurrent use with other central nervous system active drugs may increase adverse effects such as dizziness or confusion
Antihistamines and tricyclic antidepressants may reduce efficacy by opposing cholinergic activity
Use with caution alongside antipsychotics or benzodiazepines due to CNS depressant effects
Concomitant use with herbal supplements affecting CYP450 enzymes may alter donepezil metabolism
Co-administration with varenicline may increase neurological side effects
Drugs influencing gastric pH are unlikely to affect donepezil absorption significantly
Alcohol may exacerbate cognitive impairment or CNS side effects when taken with donepezil
Close communication between healthcare providers recommended to manage potential interactions

Preparations Of The Drug

Donepezil hydrochloride tablets: available in 5 mg, 10 mg, and 23 mg doses
Orally disintegrating tablets (ODT): available in 5 mg and 10 mg doses for patients with swallowing difficulties
Brand preparations include Aricept and generic equivalents produced by multiple manufacturers
Formulations contain inactive ingredients varying by manufacturer; refer to specific package inserts
Tablets are film-coated to mask bitter taste and protect drug stability
ODTs packaged in blister packs to preserve tablet integrity until administration
Available in prescription form only; dispensing as per approved dosing guidelines
Storage conditions: room temperature between 59° to 86°F (15° to 30°C) to maintain drug stability
Manufactured by Eisai Inc. (Aricept) and various generic pharmaceutical companies
Some preparations specifically designed to minimize gastrointestinal side effects
No approved transdermal or intravenous formulations currently available
Patient counseling provided to ensure appropriate handling of orally disintegrating tablets
Packaging typically includes patient information leaflets detailing administration and side effect profiles
Generic formulations provide cost-effective alternatives while maintaining bioequivalence
Combination products containing donepezil and memantine (e.g., Namzaric) exist but are distinct from donepezil monotherapy